Episodios

  • ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

    ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline
    May 22 2025
    Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they’re administered? David Miller, MD, joins us to review a pair of ARVO 2025 presentations that examined his clinic’s real-world administration patterns for bevacizumab (Avastin, Genentech), faricimab (Vabysmo, Genentech/Roche), and high-dose aflibercept (Eylea HD, Regeneron). What were the differences—and did they really matter? Also, Robert Wang, MD, helped us understand the state of play in the TKI pipeline as he shared data from the phase 2b ODYSSEY study. What are the latest data on CLX-AX (Clearside Biomedcial)? And where does it stack up against the other TKIs in the pipeline? Stick with us to find out.
    Más Menos
    23 m
  • GLP-1s and Risk of Age-Related Ocular Disease

    GLP-1s and Risk of Age-Related Ocular Disease
    May 16 2025
    How do GLP-1 drugs influence age-related ocular diseases such as macular degeneration and glaucoma? Moderator Lediana Goduni, MD, is joined by Alexis Warren, MD, and Joshua Uhr, MD, to examine a retrospective study published in Ophthalmology using TriNetX data to compare 5-year ocular outcomes across medication cohorts. Do these data suggest a protective benefit for GLP-1s—and does it matter for clinical practice? Tune in for their take on what’s promising, what’s premature, and what’s next.
    Más Menos
    18 m
  • Fellow Eye RRD Risk per IRIS Registry

    Fellow Eye RRD Risk per IRIS Registry
    May 8 2025
    Questions abound about fellow eye rhegmatogenous retinal detachments (RRD). How often do fellow eye develop RRD after the first one is repaired? What concomitant conditions do fellow eyes with RRD have? What risk factors exist for fellow eye RRD? And which procedures are used to repair fellow eye RRD? Moderator Barton Blackorby, MD, and panelists Louis Cai, MD, and Hong-Uyen Hua, MD, dissect the latest data on these questions from the AAO IRIS Registry and then compare how these data align with their respective clinical experiences.
    Más Menos
    17 m
  • Rates of Ocular AEs After Faricimab Injection

    Rates of Ocular AEs After Faricimab Injection
    Mar 21 2025
    What are the real-world safety data following administration of faricimab (Vabysmo, Genentech)? Maura Di Nicola, MD, and guests Sruthi Arepalli, MD, and Barton Blackorby, MD, review data from a real-world, single-center, retrospective study of approximately 4500 injections of faricimab in over 700 patients at Wills Eye Hospital. What did the data show? And do these data effect the clinical patterns of Drs. Di Nicola, Arepalli, and Blackorby?
    Más Menos
    18 m
  • Treating Geographic Atrophy (GA) In Your Practice

    Treating Geographic Atrophy (GA) In Your Practice
    Mar 5 2025
    Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.
    Más Menos
    19 m
  • Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy

    Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy
    Mar 5 2025
    Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.
    Más Menos
    22 m
  • Using OCT Angiography to Distinguish RVO and RAO

    Using OCT Angiography to Distinguish RVO and RAO
    Jan 9 2025
    How can OCT angiography help retina specialists distinguish between retinal vein occlusion (RVO) and retinal artery occlusion (RAO) in patients who present without acute findings? Using real-world cases as a backdrop, Yasha Modi, MD, and Kat Talcott, MD, discuss Dr. Modi’s approach to distinguishing RVO and RAO via OCT angiography and review which specific OCT angiography findings may indicate referral to cardiology. Later in the episode, they explore the utility and limitations of OCT angiography in patients with diabetic retinopathy. This episode is supported by Zeiss Professional Education.
    Más Menos
    18 m
  • OCT Angiography in a Real-world CSR Case

    OCT Angiography in a Real-world CSR Case
    Jan 9 2025
    What role can OCT angiography play in tracking the development of central serous retinopathy (CSR)? Yasha Modi, MD, and Kat Talcott, MD, review the use of OCT angiography in a real-world CSR case, discuss the value of selecting OCT angiography over fluorescein angiography for patients with neovascularization, and parse which populations are not a good fit for OCT angiography. This episode is supported by Zeiss Professional Education.
    Más Menos
    18 m
adbl_web_global_use_to_activate_T1_webcro805_stickypopup